Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Device Funding Would Leap By 26% In 2019 Under Trump Budget Proposal

Executive Summary

US FDA Device Center program funding would see a $131m increase under the Trump administration's budget proposal, which prioritizes "speeding innovations" in medical devices and other products the agency regulates, and closely examining what regulations need to be revised, updated or eliminated.

You may also be interested in...

US House Subpanel Would Give FDA Device Center An 8.5% Raise In 2020

A House subpanel overseeing US FDA spending approved an 8.5% boost – $33 million additional – in the agency’s device center funding for 2020, over 2019 levels. 

US Congress Extends Funds For FDA, NIH, To Dec. 8 In Bill Linked To Hurricane Relief

On the heels of a White House agreement with congressional Democratic leaders, the Senate and House quickly passed a government continuing resolution funding US FDA, NIH and other agencies as part of a Hurricane relief and debt-ceiling package, giving lawmakers until Dec. 8 to hammer out a detailed spending plan for the government in 2018.

US FDA Faces Down Complex Combo Products, Fires Up Oncology Center Of Excellence

FDA officials discuss difficulties dealing with complex combination products, the future of the agency's product centers, and promotion of industry collaboration at the Drug Information Association's annual meeting.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts